Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic AnemiaBMT CTN 0301
A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, Sirolimus/Extracorporeal Photopheresis plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the treatment of Chronic Graft-versus-Host DiseaseBMT CTN 0801
The Role of Minimal Residual Disease Testing before and after Hematopoietic Cell Transplantation for Pediatric Acute Myeloid LeukemiaONC1001
High Dose Temozolomide, Thiotepa and Carboplatin with Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy with 13-cis-retinoic Acid in Patients with Recurrent/Refractory Malignant Brain TumorsONC-032
Unrelated Donor Bone Marrow and Cord Blood Transplantation for Children with Severe Sickle Cell Disease(SCURT - Sickle Cell Unrelated Transplant Study)
BMT CTN 0601
The information on the website is intended to introduce you to some of the medical procedures and treatments which you/your child may receive when undergoing a hematopoietic progenitor cell transplant. The information on the website provides general guidelines but cannot replace the recommendations of your primary medical team. Specific patient care treatment options and procedures are the prerogative of each patient and their medical care team. You are encouraged to discuss any concerns or questions you have with your medical care team. Although every attempt has been made to post information that is clear and accurate, no guarantee is made to the reliability, completeness, relevancy, accuracy, or timeliness of the content. No liability is assumed by the Pediatric Blood and Marrow Transplant Consortium for any damages resulting from use or access to information posted on this website.